Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
1.020
-0.040 (-3.77%)
May 7, 2025, 4:00 PM EDT - Market closed

Company Description

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions.

The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications.

The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies.

It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.

Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.

Standard BioTools Inc.
Standard BioTools logo
Country United States
Founded 1999
IPO Date Feb 10, 2011
Industry Medical Devices
Sector Healthcare
Employees 818
CEO Michael Egholm

Contact Details

Address:
2 Tower Place, Suite 2000
South San Francisco, California 94080
United States
Phone 650 266 6000
Website standardbio.com

Stock Details

Ticker Symbol LAB
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001162194
CUSIP Number 34385P108
ISIN Number US34385P1084
Employer ID 77-0513190
SIC Code 3826

Key Executives

Name Position
Dr. Michael Egholm Ph.D. President, Chief Executive Officer and Director
Hanjoon Kim Chief Financial Officer
Jonathan Mickelsen Vice President and Chief Accounting Officer
Elizabeth R. Jensen Chief Human Resources Officer
Sean Mackay Chief Business Officer and Senior Vice President
Dr. Stephen A. Williams BS, MB, Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 6, 2025 10-Q Quarterly Report
May 6, 2025 8-K Current Report
Apr 30, 2025 ARS Filing
Apr 30, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025 DEF 14A Other definitive proxy statements
Mar 11, 2025 10-K Annual Report
Mar 4, 2025 SCHEDULE 13D/A Filing
Feb 26, 2025 8-K Current Report
Jan 13, 2025 8-K Current Report
Jan 10, 2025 8-K Current Report